We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Physiomics Plc | LSE:PYC | London | Ordinary Share | GB00BDR6W943 | ORD 0.4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.20 | -13.33% | 1.30 | 1.20 | 1.40 | 1.30 | 1.05 | 1.25 | 2,479,405 | 10:28:27 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 597k | -477k | -0.0035 | -3.71 | 1.76M |
Date | Subject | Author | Discuss |
---|---|---|---|
09/2/2018 07:56 | Very good news: Sp has held particularly well recently, despite some big sells the other day. Someone knew this contract was coming. Excellent rns, the monetary value 75K is irrelevant, it's the contract itself that is highly significant and further indication of strong confidence in the company and the massive potential. | minja19 | |
09/2/2018 07:51 | Moreover our CEO is delivering on his promises | zebbo | |
09/2/2018 07:49 | This must be the GSK deal. They mention it's a top 10. Not just a major. | margic | |
09/2/2018 07:49 | Another contract that will be complete before June. Nice. | margic | |
09/2/2018 07:46 | Feels like the start of what is going to become a sequence of long term game changing relationships and deals Why the mkt cap is so low is a mystery | zebbo | |
09/2/2018 07:45 | Yes - for 10 minutes | icejelly | |
09/2/2018 07:44 | Ah some news, I wonder if it's sufficient to create a share price rise? | cool hand kev | |
09/2/2018 07:42 | Very good news. Friday RNS forgiven in view of markets.Another global top 10 pharmaceutical client on board.What's PYC's market capitalisation again? Much too low. | patientcapital | |
09/2/2018 07:24 | Serious momentum behind this now. 3 Major Pharmas spending £600k with PYC when previously highest turnover never got over £200k before Dr Jim Millen is delivering more than he promised The time for In Silico Clinical Trials is coming Remember PYC talking to 50 potential clients Work it out 50 x £30k Good 50 x £70k Excellent 50 x £500k Stellar moonshoot this time next year Rodney we will all be millionaires | the stigologist | |
09/2/2018 07:18 | Steady as she goes Sir, the only way is up! Keep developing those contracts with major pharmas | ny boy | |
09/2/2018 07:15 | ...yes, and although only worth £70K, it's twice the value of the previous contract awarded a couple of weeks ago - and, as the RNS states, it's indicative of the interest majors appear to have in the tech. Good news. | jenny tulwought | |
09/2/2018 07:07 | 3rd contract win. All adds up. | looneytune | |
08/2/2018 23:21 | $500mil minus what's hidden from share holders $375mil circa, into sterling circa £250mil+, second fish bowl high if I remember right, £5.50p a share. You may be able to post one for peeps to see what I'm on about go back around 11-12 years I think. Thanks in advance, margic.Let's have a google rumour or better yet, rns tomorrow! | margic | |
08/2/2018 23:17 | There's my point. They could throw £500mil into something and it doesn't touch the sides. It's a great possible link. If the heavens wanna open up and make this thought a near term reality there will soon be some very sour faces you'll probably never have to see again on these bbs me old chum. I'd expect you be choosing an island to purchase ;) | margic | |
08/2/2018 23:10 | Just FYI Google paid $500m for an AI data company called Deepmind a couple of years back. I know it well because University friends of friends set that Company up. $500m for ZERO revenues! | the stigologist | |
08/2/2018 22:32 | Now if there were rumours of a deal with either of those two, you could be looking at a value of £2.50p to as much as £20 a share if either of them two are J.V partners. There's the fish bowl effect. Google could invest untold money developing what PYC own patents too! They would likely have the superior employees to work on tech. My understanding of the data science industry is decent and what I do know is when google come in for these guys they all generally will go. They'll also be the best at what they do. Now imagine this ''Google, PYC and J.V'' written in a sentence. That's called ringing the bell! | margic | |
08/2/2018 22:14 | I have to admit my mind is pretty set on 100p but that would only be for the B2B stuff However the potential of the B2C Cancer diagnostics stuff would be Global and stellar (I wouldn't even be able to put a figure on it right now) and as I've mentioned before you could see likes of Jeff Bezos / Google etc wanting to get involved not just the 'usual suspects' of Global MedTech firms / Pharmas | the stigologist | |
08/2/2018 18:51 | Somewhere between 60p and 120p would be agreeable Stig - USD50-100m. | patientcapital | |
08/2/2018 16:36 | Kept the door shut today. Rns soon me feels. Company update in the next few weeks would be nice! Lol thinking there's better to come than that Before that. The contract with the new major must be about to commence, hope its starts well. | margic | |
08/2/2018 14:28 | Watch there may be another chance at 7p just either side to buy, this looks ready to launch, may kick back for the spring. 240 about to golden x, daily 50ma is pointing up same as 200x technically huge weakness all over this drop, oversold. Bad news this ranks quick, no news to good news this looks like the final bounce of the spring board then lift off. Imo of course, technically speaking..... | margic | |
08/2/2018 11:09 | Big spread bit it's not that big in reality as you can buy below the ask. Wonder why they are advertising a huge spread .....put buyers offf perhaps | spacedust | |
08/2/2018 11:02 | Allowing buys sub 7.60p now | margic | |
08/2/2018 11:01 | I think that's a good couple of buys their. Watch this move when these volumes pick up. Expecting it to all start today..... | margic |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions